logo

For the Inventor, By the Inventor

Maarn, Netherlands

Joost Alexander Kolkman

This inventor holds 21 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Immunotherapy Development. Top assignees: Ablynx N.v., Janssen Vaccines & Prevention B.v., Merck Patent Gmbh. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joost Alexander Kolkman. Retrieved from https://idiyas.com/inventor/joost-alexander-kolkman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 90.5

 

Average Co-Inventor Count = 3.2

ph-index = 7

Forward Citations = 136(Granted Patents)


Location History:

  • Maarn, NL (2014 - 2021)
  • Sint-Martens-Latem, BE (2014 - 2023)

Company Filing History:

goldMedal13 out of 174 
 
Ablynx N.v.
 patents
silverMedal3 out of 117 
 
Janssen Vaccines & Prevention B.v.
 patents
bronzeMedal3 out of 3,022 
 
Merck Patent Gmbh
 patents
4. 1 out of 433 
 
Janssen Biotech, Inc.
 patents
5. 1 out of 3,977 
 
Novartis Ag
 patents
6. 1 out of 2,659 
 
University of Pennsylvania
 patents
where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Polypeptides
IL-17A
IL-6 Receptor
Influenza Hemagglutinin
AAV Vaccines
Hepatocyte Growth Factor
Immunoglobulin Sequences
Antibodies
Biologic Compounds
Cancer Treatments
Binding Molecules
Pharmaceutical Compositions
21 patents (USPTO):Explore Patents
1. 11773159 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2023-10-03),
2. 11136379 - Binding molecules directed against influenza hemagglutinin and uses thereof (2021-10-05),
3. 10829552 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same (2020-11-10),
4. 10786568 - AAV mediated influenza vaccines (2020-09-29),
5. 10703804 - Binding molecules directed against influenza hemagglutinin and uses thereof (2020-07-07),
6. 10618966 - Methods for the treatment of interleukin-6 receptor-related diseases and disorders (2020-04-14),
7. 10392440 - Methods for the preparation of compounds directed against interleukin-6 receptor (IL-6R) (2019-08-27),
8. 10370435 - Binding molecules directed against influenza hemagglutinin and uses thereof (2019-08-06),
9. 10214588 - Providing improved immunoglobulin sequences by mutating CDR and/or FR positions (2019-02-26),
10. 10100110 - Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors (2018-10-16),
11. 10017568 - Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same (2018-07-10),
12. 9670275 - Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors (2017-06-06),
13. 9617341 - Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptor (2017-04-11),
14. 9611326 - Interleukin-6 receptor binding polypeptides (2017-04-04),
15. 9605072 - Nucleic acids that encode interleukin-6 receptor binding polypeptides (2017-03-28),

Title: **Joost Alexander Kolkman: Innovator in Biomedicine**

Introduction

Joost Alexander Kolkman, located in Maarn, NL, is a prominent inventor with an impressive portfolio of 21 patents. His work primarily revolves around advancements in biomedicine, specifically targeting therapeutic methods and binding molecules related to diseases such as influenza and autoimmune disorders.

Latest Patents

Among his latest innovations, Kolkman has developed polypeptides that bind to IL-17A, IL-17F, and IL-17A/F. These amino acid sequences are designed for therapeutic applications, providing potential treatment methods for various conditions involving these interleukins. Additionally, he has patented multimeric binding molecules capable of specifically binding to hemagglutinin (HA) from multiple influenza virus strains. These binding molecules not only target strains from phylogenetic groups but also demonstrate capabilities to neutralize several influenza A and B virus strains, showcasing the significance of his research in pandemic preparedness.

Career Highlights

Throughout his career, Joost Kolkman has contributed to leading companies in the biopharmaceutical sector, including Ablynx N.V. and Janssen Vaccines & Prevention B.V. His work has yielded impactful inventions that address significant health challenges, enhancing the landscape of disease treatment and prevention.

Collaborations

Kolkmans’s journey has been bolstered by collaborative efforts with renowned colleagues such as Els Anna Alice Beirnaert and Cedric Jozef Neotere Ververken. These partnerships have facilitated groundbreaking advancements and the successful development of innovative therapies.

Conclusion

In summary, Joost Alexander Kolkman stands out as a visionary inventor in the field of biomedicine. With his extensive patent portfolio and notable collaborations, he continues to make significant contributions to health science, aiming for a future where innovative treatments are readily available to combat various ailments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…